Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study

Aligos Therapeutics, Inc. ALGS has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201.

Lawrence Blatt, CEO and Chairman, said: This is an important next step in our evaluation of ALG-000184 as a chronic suppressive therapy and/or part of a functional cure regimen in patients with CHB. With the initiation of this 12-week cohort at the 100 mg dose level, we can now explore whether longer-term dosing continues to be well tolerated and if greater suppression of important viral parameters, including HBV DNA and RNA, in HBeAg-positive subjects can be achieved.”

Aligos indicated the oral ALG-000184 doses up to 100 mg given daily for 28 days were well tolerated with excellent pharmacokinetic properties and potentially best-in-class antiviral activity in both HBeAg-negative and -positive CHB subjects.

The company plans to share data readout from this cohort at a scientific conference in the fourth quarter of 2022.

Price Action : Aligos shares are trading around 4 percent down at $1.38 on Monday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksHealth CareGeneralClinical Study Initiation
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!